FOLH1 and prostate carcinoma: In the clinical setting, PSMA expression in prostate cancer has been utilized for diagnostic purposes with gallium-68 (68 Ga) PSMA and therapeutically with Lutetium-177 (177 Lu) PSMA [9,10].